In a recent randomized, open-label, phase 3 clinical study, researchers compared the efficacy and safety of brigatinib with those of crizotinib, in patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitor treatment [138]

Posted on by Courtney Roberts

In a recent randomized, open-label, phase 3 clinical study, researchers compared the efficacy and safety of brigatinib with those of crizotinib, in patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitor treatment [138]. the full-length ALK protein with 1620 amino acids. ALK is an enzyme with tyrosine Continue Reading